The Therapeutic Products Program of Health Canada has approved Draxis'vitamin D pro-hormone Hectorol (doxercalciferol) for the treatment of elevated parathyroid hormone levels in the blood for the management of secondary hyperparathyroidism in patients who are undergoing chronic renal dialysis and can no longer produce endogenous D-hormones.
Bone Care International, which developed Hectorol and licensed the marketing rights to the drug in Canada exclusively to Draxis, received US Food and Drug Administration approval for Hectorol capsules in 1999 and Hectorol injection last year. Charles Bishop, chief executive of Bone Care, said: "we are pleased that Hectorol is now approved in both the USA and Canada, and we plan to initiate the European registration process later this year."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze